The P450 oxidoreductase (POR) rs2868177 and cytochrome P450 (CYP) 2B6*6 polymorphisms contribute to the interindividual variability in human CYP2B6 activity

被引:9
|
作者
Gao, Li-chen [1 ]
Liu, Fang-qun [1 ]
Yang, Li [1 ]
Cheng, Lin [6 ]
Dai, Hai-ying [2 ]
Tao, Ran [2 ]
Cao, Shi-Peng [3 ]
Wang, Di [4 ]
Tang, Jie [5 ]
机构
[1] Changsha Cent Hosp, Dept Pharm, Changsha 410004, Hunan, Peoples R China
[2] Changsha Cent Hosp, Dept Cardiol, Changsha 410004, Hunan, Peoples R China
[3] Changsha Cent Hosp, Pulm Hosp, TB Res Ctr, Changsha 410004, Hunan, Peoples R China
[4] Changsha Cent Hosp, Inst Canc, Dept Oncol, Changsha 410004, Hunan, Peoples R China
[5] Cent S Univ, Inst Clin Pharmacol, Changsha 410078, Hunan, Peoples R China
[6] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China
关键词
P450; oxidoreductase; Polymorphism; CYP2B6; Interindividual variations; Bupropion hydroxylation; GENETIC POLYMORPHISMS; BUPROPION HYDROXYLATION; HUMAN LIVER; IN-VITRO; TRANSPLANT RECIPIENTS; DRUG-METABOLISM; VARIANTS; IDENTIFICATION; IMPACT; 2B6;
D O I
10.1007/s00228-016-2095-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To investigate whether single-nucleotide polymorphisms (SNPs) in the P450 oxidoreductase (POR) gene were correlated with interindividual variations in cytochrome P450 (CYP) 2B6 activity. Thirty-six healthy volunteers who tested CYP2B6 and POR polymorphisms were enrolled in the study. CYP2B6 activity was measured by bupropion hydroxylation with LC/MS/MS. The ratio of hydroxybupropion versus bupropion (AUC_hyd/AUC_bup) in terms of area under the time-concentration curve (AUC) was used to represent the CYP2B6 activity. The volunteers carrying CYP2B6*1/*1 showed a significantly higher mean AUC_hyd/ AUC_bup than those CYP2B6*1/*6 and CYP2B6*6/*6 variants (15.66 +/- A 1.65 vs. 9.25 +/- A 1.92, P = 0.008 and 15.66 +/- A 1.65 vs. 8.21 +/- A 1.74, P = 0.006, respectively). POR rs2868177 (6593 A > G) AA homozygotes showed a significantly lower mean AUC_hyd/ AUC_bup than that of POR rs2868177 AG heterozygotes or GG homozygotes (8.13 +/- A 1.37 vs. 12.15 +/- A 2.97, P = 0.005 and 8.13 +/- A 1.37 vs. 17.59 +/- A 3.25, P = 0.001, respectively). Moreover, POR rs2868177 AG heterozygotes and GG homozygotes showed a significantly increased mean AUC_hyd/AUC_bup than AA homozygotes in the CYP2B6*1/*1 and CYP2B6*6 carriers (16.40 +/- A 2.01 vs. 12.40 +/- A 1.45, P = 0.006 and 10.65 +/- A 1.47 vs. 6.54 +/- A 1.25, P = 0.004, respectively). Meanwhile, a strong correlation between the genetic variations (POR rs2868177 and CYP2B6*6) and AUC_hyd/ AUC_bup was found (P = 0.009 and P = 0.001, respectively). There was no significant difference in the mean AUC_hyd/AUC_bup among different POR *28 genotypes (P > 0.05). POR rs2868177 and CYP2B6*6 variants contribute to the interindividual variability in human CYP2B6 activity, which may affect the disposition and interaction of other CYP2B6 substrate drugs.
引用
收藏
页码:1205 / 1213
页数:9
相关论文
共 50 条
  • [31] Structural and Thermodynamic Basis of (+)-α-Pinene Binding to Human Cytochrome P450 2B6
    Wilderman, P. Ross
    Shah, Manish B.
    Jang, Hyun-Hee
    Stout, C. David
    Halpert, James R.
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2013, 135 (28) : 10433 - 10440
  • [32] Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline
    Paulo Roberto Xavier Tomaz
    Mariana Soares Kajita
    Juliana Rocha Santos
    Jaqueline Scholz
    Tânia Ogawa Abe
    Patrícia Viviane Gaya
    José Eduardo Krieger
    Alexandre Costa Pereira
    Paulo Caleb Júnior Lima Santos
    European Journal of Clinical Pharmacology, 2019, 75 : 1541 - 1545
  • [33] Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline
    Xavier Tomaz, Paulo Roberto
    Kajita, Mariana Soares
    Santos, Juliana Rocha
    Scholz, Jaqueline
    Abe, Tania Ogawa
    Gaya, Patricia Viviane
    Krieger, Jose Eduardo
    Pereira, Alexandre Costa
    Junior Lima Santos, Paulo Caleb
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 (11) : 1541 - 1545
  • [34] Mechanism-based inactivation of cytochrome P450 2B6 by isoimperatorin
    Cao, Jiaojiao
    Zheng, Liwei
    Ji, Lin
    Lu, Dan
    Peng, Ying
    Zheng, Jiang
    CHEMICO-BIOLOGICAL INTERACTIONS, 2015, 226 : 23 - 29
  • [35] Mechanism-based inactivation of cytochrome P450 2B6 by methadone
    Amunugama, Hemali
    DRUG METABOLISM REVIEWS, 2011, 43 : 65 - 66
  • [36] Mechanism-based inactivation of cytochrome P450 2B6 by isopsoralen
    Lu, Dan
    Ji, Lin
    Zheng, Liwei
    Cao, Jiaojiao
    Peng, Ying
    Zheng, Jiang
    XENOBIOTICA, 2016, 46 (04) : 335 - 341
  • [37] Marmoset cytochrome P450 2B6, a propofol hydroxylase expressed in liver
    Oshio, Toru
    Uehara, Shotaro
    Uno, Yasuhiro
    Inoue, Takashi
    Sasaki, Erika
    Yamazaki, Hiroshi
    XENOBIOTICA, 2019, 49 (03) : 265 - 269
  • [38] Cytochrome P450 2B6 Amperometric Biosensor for Continuous Monitoring of Propofol
    Ferrier, David C.
    Kiely, Janice
    Luxton, Richard
    IEEE SENSORS JOURNAL, 2021, 21 (21) : 23730 - 23736
  • [39] Vildagliptin Affects the Metabolism of Anti-Colon Cancer Drugs Catalyzed by Cytochrome P450 (CYP) 2B6
    Wang, Yu-Cun
    Kong, Ling-Ting
    Zhao, Na
    Song, Bo
    Wang, Ping
    LATIN AMERICAN JOURNAL OF PHARMACY, 2017, 36 (11): : 2306 - 2310
  • [40] Halogen-π Interactions in the Cytochrome P450 Active Site: Structural Insights into Human CYP2B6 Substrate Selectivity
    Shah, Manish B.
    Liu, Jingbao
    Zhang, Qinghai
    Stout, C. David
    Halpert, James R.
    ACS CHEMICAL BIOLOGY, 2017, 12 (05) : 1204 - 1210